JAMA:维生素D3补充不能降低哮喘患儿恶化风险

2020-08-26 MedSci原创 MedSci原创

研究认为,对于持续哮喘且维生素D水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险

严重的哮喘恶化会导致一系列不良事件以及昂贵的医疗支出,近日研究人员考察了维生素D3补充治疗对改善低维生素D水平哮喘儿童严重恶化时间的影响。
 
 
VDKA研究中,6-16岁的哮喘严重恶化高危儿童参与,患儿接受低剂量的吸入激素治疗,基线25羟基维生素D水平低于30 ng/mL,在丙酸氟替卡松维持治疗基础上,随机接受每日4000IU维生素D3补充治疗(n=96)或安慰剂(n=96),持续48周。研究的主要终点为哮喘严重恶化时间,次要终点为病毒引起的严重恶化、吸入激素剂量减少50%的患者比例以及累积的氟替卡松剂量。
 
192名患儿参与研究,平均年龄9.8岁,女孩占40%,93.8%的患儿完成研究。维生素D3组36名患儿(37.5%)以及安慰剂组33名患儿(34.4%)出现至少1次哮喘严重恶化。与安慰剂相比,维生素D3补充治疗不能改善严重恶化时间,维生素D3组恶化平均时间为240天,安慰剂组为253天(HR=1.13)。
与安慰剂相比,维生素D3补充不能改善病毒引起的严重恶化,吸入激素剂量减少的比例或累积剂量。组间不良事件风险相似。
 
研究认为,对于持续哮喘且维生素D水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-12-13 shiyanqing

    阴性结果

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms4000002082197205

    好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 14818eb4m67暂无昵称

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    相关资讯请继续分享,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 ms7000000689223974

    很好很详细,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-27 莉莉安 Lillian C.

    好吧

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 zhaojie88

    持续#哮喘##维生素D#水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=907515, encodeId=9dae90e515f8, content=阴性结果, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e462271105, createdName=shiyanqing, createdTime=Sun Dec 13 09:34:52 CST 2020, time=2020-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814197, encodeId=c5f281419e7b, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:28 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814196, encodeId=675e814196eb, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ce05381686, createdName=ms4000002082197205, createdTime=Thu Aug 27 18:21:24 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=814013, encodeId=3a268140134a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Thu Aug 27 12:24:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813952, encodeId=71c381395283, content=相关资讯请继续分享,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:13:52 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813892, encodeId=e6ba81389265, content=很好很详细,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200823/ece0a24ea5824924b9ba0b87a5947f86/11f20d29045c49fd9671ef69fa0c4012.jpg, createdBy=f64a5412720, createdName=ms7000000689223974, createdTime=Thu Aug 27 10:03:35 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813855, encodeId=04ef8138550a, content=好吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200803/bf55cfcb09b74a0cbf751a980fe04576/e4480eaa47ab42da91303dd1c72e723e.jpg, createdBy=89fd5188713, createdName=莉莉安 Lillian C., createdTime=Thu Aug 27 08:53:31 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813563, encodeId=8b44813563db, content=持续<a href='/topic/show?id=052d399242a' target=_blank style='color:#2F92EE;'>#哮喘#</a>且<a href='/topic/show?id=5b0fe906618' target=_blank style='color:#2F92EE;'>#维生素D#</a>水平较低的患儿,补充维生素D3不能降低患者哮喘恶化风险,表明维生素D作用是很弱的, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39924, encryptionId=052d399242a, topicName=哮喘), TopicDto(id=79066, encryptionId=5b0fe906618, topicName=维生素D)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 26 21:23:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036241, encodeId=451f1036241e2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Aug 26 19:17:28 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=813495, encodeId=d80e813495b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Wed Aug 26 17:56:34 CST 2020, time=2020-08-26, status=1, ipAttribution=)]
    2020-08-26 ms3000000546723755

    学习了

    0

相关资讯

Eur Respir J:哮喘患者骨质疏松和脆性骨折发病率

哮喘患者比普通人群更容易发生骨质疏松症或FF,尤其是年轻人和使用OCS和ICS的个体。

BMJ:哮喘患者自我管理模式对医疗干预和生活质量的影响

哮喘患者使用定期医疗支持的自我管理可减少医疗资源使用,并改善哮喘的严重程度和生活质量

JAMA Intern Med :雷雨天前夕慢阻肺或哮喘发作增加!

近日,一项美国研究发现,雷雨天暴发前夕,哮喘和慢阻肺等呼吸道疾病急诊患者人数明显增加。研究者回顾医保数据,就1999~2012年间65岁以上有呼吸疾病者前往急诊就诊情况和当时天气情况进行了分析。

J Allergy Clin Immunol:哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加

急性呼吸道病毒感染是呼吸道发病和死亡的主要原因,尤其是对于已有肺部疾病如哮喘的患者。Toll样受体(TLRs)在早期病毒检测和激活呼吸道黏膜先天性免疫中起着关键作用,但目前还没有可靠、方便的方法来检测

Eur Respir J:芬兰青年男性哮喘、变应性鼻炎和特应性湿疹的长期趋势

在芬兰,年轻男性的哮喘和过敏性疾病从1960年代中期开始增加很明显。增长速度在2000年代有所放缓,并可能在2020年代趋于平稳。

BMJ:与儿童哮喘相关的空气及家庭因素研究

PM2.5是诱发儿童哮喘和持续性喘息的重要风险因素,其他相关的危险因素包括父母哮喘、父母社会经济地位和孕期吸烟